EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program

Daisuke Kotani, Atsuo Takashima, Takeshi Kato, Taroh Satoh, Toshiki Masuishi, Yoshito Komatsu, Manabu Shiozawa, Taito Esaki, Naoki Izawa, Shinji Takeuchi, Hideaki Bando, Satoru Iwasa und 7 weitere

Clinical Colorectal Cancer · 2024

DOI: 10.1016/j.clcc.2024.02.002 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Colorectal Cancer, 2024. Verfasst von Daisuke Kotani und 18 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Center Hospital East, Chiba, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Carbamates, Cetuximab. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ono Pharmaceutical Co Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The phase 3 BEACON CRC study demonstrated the survival benefits of encorafenib and cetuximab, with or without binimetinib (the BEACON triplet or doublet regimen), for BRAFV600E-mutant metastatic colorectal cancer (mCRC). This expanded access program (EAP) and subsequent follow-up study assessed the efficacy and safety of the BEACON triplet regimen in Japanese patients with BRAFV600E-mutant mCRC. MATERIALS AND METHODS: The EAP was an open-label, single-arm study including Japanese patients with BRAFV600E-mutant mCRC whose disease progressed after 1 to 2 prior regimens. The patients received the BEACON triplet regimen with 28-day cycles. The subsequent follow-up study assessed the survival outcomes following EAP completion. Safety was assessed only during the EAP. RESULTS: Among the 86 enrolled patients, 81 received the BEACON triplet regimen. The objective response rate and median progression-free survival were 27.6% (95% confidence interval [CI], 18.0%-39.1%) and 5.26 (95% CI, 4.14-5.52) months, respectively. Grade 3 to 4 adverse events and treatment-related adverse events occurred in 43.2% and 28.4% of patients, respectively. No new safety signals were observed during the EAP. Among 58 patients with confirmed survival at EAP completion, 57 were included in the follow-up study. With a median observation period of 9.17 months through the EAP and follow-up study, the median overall survival was 10.38 (95% CI, 9.00-16.16) months. CONCLUSION: The efficacy and safety of the BEACON triplet regimen in Japanese patients with BRAFV600E-mutant mCRC were consistent with those reported in the BEACON CRC trial, supporting its use as a standard treatment for pretreated patients with BRAFV600E-mutant mCRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBenzimidazolesCarbamatesCetuximabColorectal NeoplasmsSulfonamidesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedEast Asian PeopleFollow-Up StudiesJapanMutationProgression-Free SurvivalProto-Oncogene Proteins B-raf

Stichwörter der Autor:innen

BRAF inihibitorBRAF(V600E)mutationEAPMEK inhibitormCRC

Substanzen

BenzimidazolesbinimetinibBRAF protein, humanCarbamatesCetuximabencorafenibProto-Oncogene Proteins B-rafSulfonamides

Autor:innen und Institutionen

  • National Cancer Center Hospital East, Chiba, Japan.
  • National Cancer Center Hospital, Tokyo, Japan.
  • NHO Osaka National Hospital, Osaka, Japan.
  • Osaka University Hospital, Osaka, Japan.
  • Aichi Cancer Center Hospital, Aichi, Japan.
  • Hokkaido University Hospital, Sapporo-shi, Japan.

Förderung

  • Ono Pharmaceutical Co Ltd

Zitieren

APA

Kotani, D., Takashima, A., Kato, T., Satoh, T., Masuishi, T., Komatsu, Y., Shiozawa, M., Esaki, T., Izawa, N., Takeuchi, S., Bando, H., Iwasa, S., Hasegawa, H., Yamaguchi, T., Taniguchi, H., Ushida, Y., Oizaki, T., Inoue, C., & Yoshino, T. (2024). Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2024.02.002

Vancouver

Kotani D, Takashima A, Kato T, Satoh T, Masuishi T, Komatsu Y, et al. Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program. Clinical Colorectal Cancer. 2024. doi:10.1016/j.clcc.2024.02.002

BibTeX
@article{Kotani2024,
  author = {Kotani, Daisuke and Takashima, Atsuo and Kato, Takeshi and Satoh, Taroh and Masuishi, Toshiki and Komatsu, Yoshito and Shiozawa, Manabu and Esaki, Taito and Izawa, Naoki and Takeuchi, Shinji and Bando, Hideaki and Iwasa, Satoru and Hasegawa, Hiroko and Yamaguchi, Toshifumi and Taniguchi, Hiroya and Ushida, Yasunori and Oizaki, Toshiya and Inoue, Chiaki and Yoshino, Takayuki},
  title = {Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program},
  journal = {Clinical Colorectal Cancer},
  year = {2024},
  doi = {10.1016/j.clcc.2024.02.002}
}
Kostenlos starten →